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Empagran S.A. v. F. Hoffman-Laroche, Ltd.:
DC Circuit Restricts Reach of US Antitrust
Laws over Injuries Sustained in Foreign
Commerce
Leon Greenfield and David Olsky
Abstract
On June 28, 2005, the US Court of Appeals for the District of Columbia issued
an important opinion on the extraterritorial reach of the US antitrust laws in Em-
pagran S.A. v. F. Hoffman-Laroche, Ltd. The court held, on remand from the
Supreme Court, that plaintiffs injured outside US commerce cannot bring antitrust
suits in US courts unless the US effects of the anticompetitive conduct at issue are
the proximate cause of their injuries. The decision construes narrowly the circum-
stances under which plaintiffs may be able to sue in US courts for injuries suffered
in foreign commerce.
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On June 28, 2005, the US Court of Appeals 
for the District of Columbia issued an 
important opinion on the extraterritorial 
reach of the US antitrust laws in Empagran 
S.A. v. F. Hoffman-Laroche, Ltd.1 The court 
held, on remand from the Supreme Court, 
that plaintiffs injured outside US commerce 
cannot bring antitrust suits in US courts 
unless the US effects of the anticompetitive 
conduct at issue are the proximate cause 
of their injuries. The decision construes 
narrowly the circumstances under which 
plaintiffs may be able to sue in US courts 
for injuries suffered in foreign commerce.
Background
Empagran was a class action brought by 
plaintiffs that had purchased vitamins 
overseas. They alleged that vitamin 
manufacturers had participated in 
a global price-ﬁxing conspiracy that 
raised prices both for the vitamins they 
purchased overseas and for the vitamins 
that others purchased in US commerce. 
The critical issue in Empagran was 
whether the Foreign Trade and Antitrust 
Improvement Acts of 1982 (FTAIA) 
barred the purchasers from bringing 
antitrust claims in US courts. The FTAIA 
prohibits antitrust suits for transactions 
in foreign commerce—that is, commerce 
taking place entirely outside the United 
States—unless the plaintiff can show that:
(1) The alleged harmful conduct 
had a “direct, substantial, and 
reasonably foreseeable effect” 
on US commerce; and
(2) The effect on US commerce gave rise 
to “a” claim under the Sherman Act.
Last year, in a closely watched decision, 
F. Hoffman-Laroche, Ltd. v. Empagran S.A., 
542 US 155 (2004), the Supreme Court 
held that the FTAIA barred the purchasers 
from bringing their claims in US courts if 
their injuries were “independent” of the 
conspiracy’s effects in US commerce. The 
Court did not, however, ﬁnally resolve the 
case. The purchasers had argued to the 
Court that their injuries were “linked” to 
the US effects of the conspiracy because 
manufacturers needed to keep prices 
high in the United States to prevent US 
vitamin purchasers from proﬁtably reselling 
vitamins in foreign countries (and thereby 
undermining the success of the conspiracy 
in those countries). The purchasers 
argued that their injuries were therefore 
not “independent” of the conspiracy’s 
effects in US commerce. The Supreme 
Court remanded the case to the DC 
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Circuit to determine the validity of this 
argument (and if the argument had been 
properly preserved in the lower courts). 
Following the Supreme Court’s Empagran 
decision, there was great uncertainty 
about the scope and practical effects of 
the potential opening left for plaintiffs 
purchasing outside the United States to 
sue in US courts for injuries that were 
not “independent” of the conspiracy’s US 
effects. In particular, the Court had failed 
to deﬁne what “independent” meant. The 
question became whether the courts 
would deﬁne the term “independent” so as 
to give rise to US jurisdiction whenever a 
purchaser in foreign commerce could allege 
that its injuries were in some way caused by 
the conspiracy’s effects in US commerce.
The DC Circuit Opinion
On remand, the DC Circuit held that the 
purchasers’ injuries were not sufﬁciently 
linked to the alleged conspiracy’s effect on 
US commerce to support US jurisdiction 
over their antitrust claims. The court ﬁrst 
observed that antitrust injuries sustained 
in foreign commerce may be redressed in 
US Courts in only limited circumstances. 
To obtain relief, plaintiffs must show 
that their injuries bear a “direct causal 
relationship” to the US effects of the 
alleged anticompetitive conduct. In other 
words, the US effects of anticompetitive 
conduct must be the “proximate cause” 
of the plaintiffs’ injury rather than simply 
a “but-for” cause thereof. The court 
noted that this interpretation of the FTAIA 
accords with the principles of “prescriptive 
comity”—i.e., “the respect sovereign 
nations afford each other by limiting the 
reach of their laws”—that the Supreme 
Court endorsed in its Empagran opinion. 
The DC Circuit then held that the US 
courts lacked jurisdiction over the 
purchasers’ claims because the US effects 
of the manufacturers’ conspiracy were 
not the proximate cause of the purchasers’ 
alleged injuries. The court observed that 
the direct cause (and thus the proximate 
cause) of the purchasers’ injuries was 
in fact the foreign effects of the global 
conspiracy—i.e., the artiﬁcially inﬂated 
prices of vitamins sold in foreign countries. 
The court recognized that the ﬁxing of 
vitamin prices in the United States may 
have facilitated the manufacturers’ ﬁxing of 
vitamin prices in foreign countries, and that 
the manufacturers may have foreseen or 
intended this result. It concluded, however, 
that the artiﬁcially inﬂated vitamin prices 
in the United States were only an indirect 
cause—not a “proximate cause”—of the 
purchasers’ injury in overseas markets. 
There was no “direct tie” between the US 
effects and the injuries that the purchasers 
sustained. Accordingly, the effects of the 
conspiracy on US commerce did not 
“give rise to” the purchasers’ claims as 
required by the FTAIA, and the purchasers 
were barred from suing in US courts.
Implications of the Decision 
The DC Circuit’s decision on remand 
suggests that courts of appeal may 
construe the term “independent” so as 
to bar under the FTAIA claims for injuries 
suffered in foreign commerce that are not 
directly tied to effects in US commerce. 
The DC Circuit’s decision, along with the 
Second Circuit’s decision in Sniado v. Bank 
Austria AG, 378 F.3d 210 (2d Cir. 2004), 
indicate that the appellate courts are 
taking very seriously the comity concerns 
that the Supreme Court articulated in its 
Empagran opinion, and that they will be 
reluctant to extend US jurisdiction over 
antitrust claims to transactions taking 
place strictly in foreign commerce. 
It bears noting, however, that the DC 
Circuit’s decision in Empagran is not the 
last word in the long-running debate about 
what exactly the FTAIA means. At least one 
district court decision, In re Monosodium 
Glutamate Antitrust Litigation, 2005 WL 
1080790 (D. Minn. May 2, 2005), held that 
plaintiffs purchasing fungible goods overseas 
had sufﬁciently alleged a direct tie between 
their injuries and the US effects of a global 
price-ﬁxing conspiracy so as to overcome 
the FTAIA’s jurisdictional limitations. 
Furthermore, the plaintiffs in Empagran will 
probably seek rehearing from an en banc 
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panel of the DC Circuit or ﬁle a petition 
for certiorari with the Supreme Court. We 
expect that the DC Circuit’s “proximate 
cause” standard is likely to prove inﬂuential 
in future cases involving the FTAIA, but 
the denouement of the whole FTAIA 
saga may not yet have been written.
Leon Greenﬁeld and David Olsky 
authored this update.
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